Cargando…

Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes

OBJECTIVES: Venlafaxine (VLX), a serotonine-noradrenaline reuptake inhibitor, is one of the most commonly used antidepressant drugs in clinical practice for the treatment of major depressive disorder (MDD). Despite being more potent than its predecessors, similarly to them, the therapeutical effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamási, Viola, Petschner, Peter, Adori, Csaba, Kirilly, Eszter, Ando, Romeo D., Tothfalusi, Laszlo, Juhasz, Gabriella, Bagdy, Gyorgy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244101/
https://www.ncbi.nlm.nih.gov/pubmed/25423262
http://dx.doi.org/10.1371/journal.pone.0113662
_version_ 1782346186444767232
author Tamási, Viola
Petschner, Peter
Adori, Csaba
Kirilly, Eszter
Ando, Romeo D.
Tothfalusi, Laszlo
Juhasz, Gabriella
Bagdy, Gyorgy
author_facet Tamási, Viola
Petschner, Peter
Adori, Csaba
Kirilly, Eszter
Ando, Romeo D.
Tothfalusi, Laszlo
Juhasz, Gabriella
Bagdy, Gyorgy
author_sort Tamási, Viola
collection PubMed
description OBJECTIVES: Venlafaxine (VLX), a serotonine-noradrenaline reuptake inhibitor, is one of the most commonly used antidepressant drugs in clinical practice for the treatment of major depressive disorder (MDD). Despite being more potent than its predecessors, similarly to them, the therapeutical effect of VLX is visible only 3–4 weeks after the beginning of treatment. Furthermore, recent papers show that antidepressants, including also VLX, enhance the motor recovery after stroke even in non depressed persons. In the present, transcriptomic-based study we looked for changes in gene expressions after a long-term VLX administration. METHODS: Osmotic minipumps were implanted subcutaneously into Dark Agouti rats providing a continuous (40 mg/kg/day) VLX delivery for three weeks. Frontal regions of the cerebral cortex were isolated and analyzed using Illumina bead arrays to detect genes showing significant chances in expression. Gene set enrichment analysis was performed to identify specific regulatory networks significantly affected by long term VLX treatment. RESULTS: Chronic VLX administration may have an effect on neurotransmitter release via the regulation of genes involved in vesicular exocytosis and receptor endocytosis (such as Kif proteins, Myo5a, Sv2b, Syn2 or Synj2). Simultaneously, VLX activated the expression of genes involved in neurotrophic signaling (Ntrk2, Ntrk3), glutamatergic transmission (Gria3, Grin2b and Grin2a), neuroplasticity (Camk2g/b, Cd47), synaptogenesis (Epha5a, Gad2) and cognitive processes (Clstn2). Interestingly, VLX increased the expression of genes involved in mitochondrial antioxidant activity (Bcl2 and Prdx1). Additionally, VLX administration also modulated genes related to insulin signaling pathway (Negr1, Ppp3r1, Slc2a4 and Enpp1), a mechanism that has recently been linked to neuroprotection, learning and memory. CONCLUSIONS: Our results strongly suggest that chronic VLX treatment improves functional reorganization and brain plasticity by influencing gene expression in regulatory networks of motor cortical areas. These results are consonant with the synaptic (network) hypothesis of depression and antidepressant-induced motor recovery after stroke.
format Online
Article
Text
id pubmed-4244101
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42441012014-12-05 Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes Tamási, Viola Petschner, Peter Adori, Csaba Kirilly, Eszter Ando, Romeo D. Tothfalusi, Laszlo Juhasz, Gabriella Bagdy, Gyorgy PLoS One Research Article OBJECTIVES: Venlafaxine (VLX), a serotonine-noradrenaline reuptake inhibitor, is one of the most commonly used antidepressant drugs in clinical practice for the treatment of major depressive disorder (MDD). Despite being more potent than its predecessors, similarly to them, the therapeutical effect of VLX is visible only 3–4 weeks after the beginning of treatment. Furthermore, recent papers show that antidepressants, including also VLX, enhance the motor recovery after stroke even in non depressed persons. In the present, transcriptomic-based study we looked for changes in gene expressions after a long-term VLX administration. METHODS: Osmotic minipumps were implanted subcutaneously into Dark Agouti rats providing a continuous (40 mg/kg/day) VLX delivery for three weeks. Frontal regions of the cerebral cortex were isolated and analyzed using Illumina bead arrays to detect genes showing significant chances in expression. Gene set enrichment analysis was performed to identify specific regulatory networks significantly affected by long term VLX treatment. RESULTS: Chronic VLX administration may have an effect on neurotransmitter release via the regulation of genes involved in vesicular exocytosis and receptor endocytosis (such as Kif proteins, Myo5a, Sv2b, Syn2 or Synj2). Simultaneously, VLX activated the expression of genes involved in neurotrophic signaling (Ntrk2, Ntrk3), glutamatergic transmission (Gria3, Grin2b and Grin2a), neuroplasticity (Camk2g/b, Cd47), synaptogenesis (Epha5a, Gad2) and cognitive processes (Clstn2). Interestingly, VLX increased the expression of genes involved in mitochondrial antioxidant activity (Bcl2 and Prdx1). Additionally, VLX administration also modulated genes related to insulin signaling pathway (Negr1, Ppp3r1, Slc2a4 and Enpp1), a mechanism that has recently been linked to neuroprotection, learning and memory. CONCLUSIONS: Our results strongly suggest that chronic VLX treatment improves functional reorganization and brain plasticity by influencing gene expression in regulatory networks of motor cortical areas. These results are consonant with the synaptic (network) hypothesis of depression and antidepressant-induced motor recovery after stroke. Public Library of Science 2014-11-25 /pmc/articles/PMC4244101/ /pubmed/25423262 http://dx.doi.org/10.1371/journal.pone.0113662 Text en © 2014 Tamási et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tamási, Viola
Petschner, Peter
Adori, Csaba
Kirilly, Eszter
Ando, Romeo D.
Tothfalusi, Laszlo
Juhasz, Gabriella
Bagdy, Gyorgy
Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes
title Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes
title_full Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes
title_fullStr Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes
title_full_unstemmed Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes
title_short Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes
title_sort transcriptional evidence for the role of chronic venlafaxine treatment in neurotrophic signaling and neuroplasticity including also glutatmatergic- and insulin-mediated neuronal processes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244101/
https://www.ncbi.nlm.nih.gov/pubmed/25423262
http://dx.doi.org/10.1371/journal.pone.0113662
work_keys_str_mv AT tamasiviola transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses
AT petschnerpeter transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses
AT adoricsaba transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses
AT kirillyeszter transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses
AT andoromeod transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses
AT tothfalusilaszlo transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses
AT juhaszgabriella transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses
AT bagdygyorgy transcriptionalevidencefortheroleofchronicvenlafaxinetreatmentinneurotrophicsignalingandneuroplasticityincludingalsoglutatmatergicandinsulinmediatedneuronalprocesses